Patheon bolsters regulatory offering through Swiftwater deal

- Last updated on GMT

Related tags: Pharmacology

Patheon has teamed up with drug development consultant Swiftwater to offer customers advice and guidance on regulatory and compliance issues.

Washington DC, US headquartered Swiftwater will help Patheon’s clients navigate the increasingly choppy regulatory seas, providing advice on drug development, documentation and product submission.

Patheon CEO Wes Wheeler said the partnership provides a useful expansion of the firm’s portfolio, explaining that: “Many of our clients benefit from strategic and tactical assistance with their NDA filings, 505(b) 2 filings, bioequivalence requirements, technical transfers and paediatric line extension strategies​.”

Thomas Fritz, Managing Partner of Swiftwater added that the partnership will cover “the full development spectrum from pre-clinical to regulatory approval, at the same time ensuring tight coordination of manufacture, nonclinical program development and execution, clinical study design and execution, and regulatory documentation​."

Related news

Show more

Related products

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Follow us


View more